# DESCRIPTION

## ACKNOWLEDGMENT OF GOVERNMENT SUPPORT

- acknowledge government support

## FIELD

- define field of disclosure

## BACKGROUND

- describe TGF-β functions
- describe TGF-β role in diseases

## SUMMARY

- introduce engineered TGF-β monomers
- describe recombinant TGF-β monomer
- describe fusion proteins and compositions
- describe methods of inhibiting TGF-β signaling

## DETAILED DESCRIPTION

### I. Abbreviations

- define abbreviations

### II. Terms and Methods

- motivate terms and methods
- define aberrant TGF-β signaling
- define administration
- define contacting
- define fibrosis
- define fusion protein
- define glycosylation
- define heterologous
- define isolated
- define monomer
- define neoplasia
- define PEGylation
- define peptide or polypeptide
- explain conservative amino acid substitutions
- define pharmaceutically acceptable carriers
- define preventing, treating or ameliorating a disease
- define recombinant
- explain sequence identity/similarity
- describe methods of alignment of sequences
- define subject
- define tag
- define therapeutically effective amount
- define transforming growth factor-β (TGF-β)
- define TGF-β signaling pathway
- define TGF-β receptor
- explain TGF-β receptors
- clarify technical and scientific terms
- explain singular and plural terms
- provide general information on references and materials

### III. Overview of Several Embodiments

- introduce recombinant TGF-β monomers
- describe inhibition of TGF-β signaling
- specify use in treating diseases or disorders
- detail cysteine to serine substitution
- describe deletion of amino acid residues 52-71
- explain effect of deletion on α-helical 3 region
- specify at least one amino acid substitution
- describe increase in net charge of monomer
- specify human, mouse, rat or other mammalian TGF-β monomer
- describe at least one amino acid substitution for MIL affinity
- specify human TGF-β2 monomer
- detail leucine to arginine substitution at residue 51
- detail alanine to lysine substitution at residue 73
- describe combination of substitutions
- specify residues for TβRII affinity
- describe lysine to arginine at residue 25
- describe arginine to lysine at residue 26
- describe leucine to valine at residue 89
- describe isoleucine to valine at residue 92
- describe asparagine to arginine at residue 94
- describe threonine to lysine at residue 95
- describe isoleucine to valine at residue 98
- specify SEQ ID NO: 8 or SEQ ID NO: 10

### IV. Administration of Engineered TGF-β Monomers

- introduce pharmaceutical compositions
- describe isolated cell compositions
- specify pharmaceutically acceptable carriers
- detail parenteral formulations
- describe solid compositions
- specify auxiliary substances
- describe administration methods
- specify dosage forms
- describe unit dosage form

## EXAMPLES

### Example 1: An Engineered TGF-β Monomer that Functions as a Dominant Negative to Block TGF-β Signaling

- describe engineered TGF-β monomer

### BACKGROUND

- introduce TGF-β1 and TGF-β3 monomers
- describe limitations of TGF-β1 and TGF-β3 monomers
- hypothesize non-covalent dimerization of TGF-β monomers
- design engineered monomer to inhibit TGF-beta signaling
- replace interfacial α-helix with flexible loop
- limit potential of monomers to non-covalently dimerize
- eliminate contact surface for TGF-β type I receptor
- summarize nomenclature and features of dimeric and monomeric TGF-β
- show complete sequences of TGF-β variants
- express and purify human MI ectodomain
- express and purify human TβRII ectodomain
- describe protein expression and purification methods
- express and purify avi-tagged homodimeric TGF-β3
- express and purify mini monomeric TGF-β1
- express and purify mini monomeric TGF-β2
- express and purify mini monomeric TGF-β3
- express and purify mini monomeric TGF-β2 with seven substitutions
- express and purify avi-tagged mini monomeric TGF-β2 with seven substitutions
- describe solubility assays
- measure light scattering and absorbance
- describe NMR spectroscopy methods
- prepare NMR samples
- acquire and analyze NMR data
- describe SPR binding measurements
- immobilize TGF-β2 and mmTGF-β2 on sensor chip
- perform SPR experiments with TGF-β3 and mmTGF-β2-7M
- describe crystallization and structure determination methods
- determine structure of mmTGF-β2
- determine structure of mmTGF-β2-7M:TβRII complex
- determine structure of mmTGF-β2-7M
- describe luciferase assays
- describe time-resolved FRET assays
- introduce analytical ultracentrifugation
- describe sedimentation velocity experiment
- analyze data with UltraScan
- summarize results in Table 4 and FIGS. 11-13
- motivate design of engineered mini-monomeric TGF-β
- describe structure of TGF-β receptor complexes
- hypothesize role of α-helix 3 in self-association and receptor binding
- design bacterial expression constructs for TGF-β1, -β2, and -β3
- describe deletion of α-helix 3 and substitution of Cys-77 with serine
- explain rationale for increasing net charge at pH 7.0
- isolate and characterize mmTGF-β1, -β2, and -β3
- describe folding and purification of mini-monomers
- compare solubility of mmTGF-β1, -β2, and -β3
- characterize mmTGF-β2 by NMR spectroscopy
- analyze secondary structure propensities of mmTGF-β2
- determine three-dimensional structure of mmTGF-β2 by X-ray crystallography
- compare structure of mmTGF-β2 with TGF-β2
- examine receptor binding properties of mmTGF-β2 by SPR
- compare binding of mmTGF-β2 with TGF-β2
- evaluate solubility of mmTGF-β2 at neutral pH
- compare solubility of mmTGF-β2 with TGF-β2 and mTGF-β2
- analyze NMR spectra of mmTGF-β2 in presence of CHAPS
- eliminate soluble aggregates of mmTGF-β2 with CHAPS
- record NMR spectra in presence of 10 mM CHAPS
- summarize results of mmTGF-β2 characterization
- introduce mmTGF-β2-7M
- describe physical characterization
- describe folding and homogeneity evaluation
- describe solubility evaluation
- describe three-dimensional structure determination
- compare structure with TGF-β2
- describe TβRII binding affinity measurement
- describe mmTGF-β2-7M·TβRII complex structure determination
- compare complex structure with TGF-β3·TβRII complex
- describe inhibitory activity assessment
- describe signaling activity measurement
- describe competition experiment
- describe IC50 value determination
- describe inhibition of TGF-β signaling
- describe mechanism of inhibition
- describe TβRI recruitment experiment
- describe SPR experiment
- describe analytical ultracentrifugation experiment
- describe time-resolved fluorescence resonance energy transfer experiment
- describe TR-FRET assay demonstration
- compare TR-FRET signals of mTGF-β3 and mmTGF-β2-7M
- describe effect of heel helix removal on dimer formation
- describe effect of heel helix removal on TβRI recruitment
- summarize mmTGF-β2-7M properties
- describe mmTGF-β2-7M as dominant negative inhibitor
- describe potential applications of mmTGF-β2-7M
- discuss advantages of mmTGF-β2-7M over other TGF-β isoforms
- discuss potential limitations of mmTGF-β2-7M
- conclude mmTGF-β2-7M as potent inhibitor of TGF-β signaling

### Discussion

- introduce TGF-βs and diseases
- motivate need for inhibitors
- describe engineered TGF-β monomer
- summarize advantages of inhibitor
- explain signaling activity of TGF-β1 C77S and TGF-β3 C77S
- describe AUC experiments
- describe TR-FRET experiments
- explain cooperative assembly of TβRI·TβRII complexes
- describe elimination of heel helix
- summarize effects of heel helix elimination
- discuss potential applications of inhibitors
- discuss scope of invention
- conclude with claims

